Skip to main content

Table 1 Study design with exposed, vaccination, and challenge statuses for PCV2 at different days post challenge (dpc) a

From: Effect of porcine circovirus type 2 (PCV2) vaccination on PCV2-viremic piglets after experimental PCV2 challenge

Group

Viremia (-42 dpc)

Vaccination (-28 dpc)

Challenge (0 dpc)

PCV2a

PCV2b

Vaccine Ab

Vaccine Bc

PCV2a

PCV2b

1

+

-

+

-

-

+

2

+

-

-

+

-

+

3

+

-

+

-

-

-

4

+

-

-

+

-

-

5

+

-

-

-

-

+

6

+

-

-

-

-

-

7

-

+

+

-

+

-

8

-

+

-

+

+

-

9

-

+

+

-

-

-

10

-

+

-

+

-

-

11

-

+

-

-

+

-

12

-

+

-

-

-

-

13

-

-

-

-

+

-

14

-

-

-

-

-

+

15

-

-

-

-

-

-

  1. aThere were seven animals in each group, and necropsy was performed at 21 dpc (70 days of age) in all cases.
  2. bVaccine A: inactivated chimeric PCV1-2 vaccine (Fostera PCV, Zoetis, Madison, NJ, USA).
  3. cVaccine B: experimental inactivated PCV2 vaccine.